Interferon type 1 may offer neuroprotection in prion diseases.


  • There is evidence that the innate immune system recognizes structurally abnormal prion protein (PrPSc), and that targeting the interferon (IFN) pathway may limit disease progression.

Why this matters

  • Elucidation of the interactions between prions and the immune system may facilitate the development of new therapeutic strategies.